A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750mg/day). The plasma concentrations of procainamide and N-acetyl procainamide were at subtherapeutic levels. Discontinuation of procainamide led to complete recovery. A bone marrow aspiration showed slight hypoplasia with normocellular marrow. Lupus erythematosus (LE) and antinuclear antibody (ANA) tests were negative. The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed. Precautionary measures for the early recognition of this grave hazard in exposed patients are advocated. The physician should be aware of this complication before initiating treatment with this drug. (Jpn Heart J 36: 483-487, 1995) 
Jpn Heart J the granulocytopenia. During the one month following the withdrawal of procainamide, the patient's granulocyte count rose to that before the administration of procainamide. After recovery, a bone marrow aspiration revealed a hypoplastic, normocellular marrow.
DISCUSSN
Granulocytopenia and/or agranulocytosis are very rare complications of sustained-release procainamide therapy. Although fewer than 30 cases1-18) of procainamide-induced granulocytopenia and/or agranulocytosis have been reported, the exact incidence of this phenomenon is unknown. Review of the English-language literature reveals certain common features in patients developing agranulocytosis secondary to procainamide. The majority of patients (75%) survived; the mean age was 64 years; there was no sex predilection. Sustainedrelease procainamide is normally excreted by the kidney, the half-life being approximately 6-8 hours. About 40-70% is excreted unchanged; the remainder is biotransformed in the liver, predominantly by N-acetylation. Although there was a definite increase in the complication as patients received more drug over longer periods, as little as 36.5gm was enough to cause agranulocytosis. The exact mechanism by which procainamide causes agranulocytosis is still unknown. Berger BE, et al19) reported on the mechanism of the agranulocytosis and/or granulocytopenia induced by procainamide. They implicated antilcukocyte antibody activity, as seen with aminopyrine, and a direct bone marrow toxic effect possibly mediated through inhibition of nucleic acid synthesis, as observed with the phenothiazines. The occurrence of a case of agranulocytosis secondary to a new sustained-release preparation of procainamide within months of its availability for clinical use merits attention. In a recent review of a sustained-release procainamide preparation, agranulocytosis was not reported. It has been suggested that slow acetylators (increased procainamide-to-NAPA ratio) are more prone to drug-induced side effects,20) but this has not been confirmed. Ellrodt AG, et al21) reported 8 patients who had shown severe neutropenia induced by sustained-release procainamide. Their patients developed severe neutropenia within 3 months of initiation of sustained-release procainamide therapy and in addition showed impaired bone marrow reserves. Interestingly, 5 of the 8 patients had just had cardiovascular surgery. They caution that patients may be at particular risk after cardiovascular surgery and that the hematologic status of these patients should be assessed frequently, particularly during the first 3 months of therapy. In the present case, our patient had received a relatively low total dose of 5.25g of procainamide, and in addition the plasma concentrations of both procainamide and NAPA were at subtherapeutic levels. These results sug-gest that it was not direct suppression of bone marrow by procainamide . Another possibility exists in the present case. Procainamide causes granulocytopenia through an immunologic mechanism, which is thought to be the mechanism in its production of a lupus-like syndrome. However, leukocyte agglutinins , such as evidenced by a positive LE test, have never been found in our patient with granulocytopenia, strongly suggesting that there is no immunologic basis for this adverse effect.
In a study by Lawson and Jick22) of 488 hospitalized patients receiving procainamide, 45 had an adverse reaction to the drug, but not one developed agranulocytosis. As previously described, neither specific dose nor duration of therapy of procainamide nor age or sex of the patient will predict individuals who will develop procainamide-induced agranulocytosis. The physician should be aware of this potentially lethal complication before initiating treatrnent with this drug. Careful follow-up is needed in patients being administered procainamide.
